GOSS — Gossamer Bio Income Statement
0.000.00%
Last trade - 00:00- $86.46m
- $148.04m
- $48.47m
Annual income statement for Gossamer Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 115 | 48.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 216 | 219 | 184 | 175 | 219 |
| Operating Profit | -216 | -219 | -184 | -59.9 | -171 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -234 | -229 | -180 | -55.6 | -170 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -234 | -229 | -180 | -56.5 | -170 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -234 | -229 | -180 | -56.5 | -170 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -234 | -229 | -180 | -56.5 | -170 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.13 | -2.71 | -1.11 | -0.25 | -0.713 |